Recent Press Releases

05/10/12 AVI BioPharma Announces First Quarter 2012 Financial Results and Recent Corporate Developments BOTHELL, WA, May 10, 2012 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII) -- Duchenne Muscular Dystrophy (DMD) and Infectious Disease Programs Continue to Advance in Clinical Development -- Strong Dataset Presented on AVI's Lead Drug Candidate Eteplirsen, Demonstrating Restoration of Dystrophin -- Long-Term Treatment Study with Eteplirsen Ongoing with 48-Week Dataset Expected Later This Year AVI BioPharma, Inc. (NASDAQ: AVII), a developer of...  05/03/12 AVI BioPharma Announces First Quarter 2012 Financial Results and Corporate Update Conference Call BOTHELL, WA, May 03, 2012 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, will report first quarter 2012 financial results after the NASDAQ Global Market closes on Thursday, May 10, 2012. Subsequently, at 5:00 p.m., Eastern Time (2:00 p.m., Pacific time), Chris Garabedian, AVI's president and CEO, will host a conference call to discuss first quarter financial results and to provide a corporate update. The conference call may be access...  04/25/12 AVI BioPharma to Present Additional Data From the Phase IIb Study of Eteplirsen for the Treatment of Duchenne Muscular Dystrophy at the 2012 AAN Annual Meeting Previously Reported Data Demonstrated Study Met Primary Endpoint BOTHELL, WA, Apr 25, 2012 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced that data from a Phase IIb study evaluating eteplirsen as a treatment for boys with Duchenne muscular dystrophy (DMD) will be presented today at the American Academy of Neurology 64th Annual Meeting in New Orleans, Louisiana. Principal investigator, Jerry R. Mendell, M.D. of Nationwide Child...  04/02/12 AVI BioPharma Announces Eteplirsen Meets Primary Endpoint, Demonstrating a Significant Increase in Dystrophin at 24 Weeks Compared to Placebo in Phase IIb Trial for the Treatment of Duchenne Muscular Dystrophy BOTHELL, WA, Apr 02, 2012 (MARKETWIRE via COMTEX) --AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced that treatment with eteplirsen met the primary efficacy endpoint in a randomized, double-blind, placebo-controlled Phase IIb study in boys with Duchenne muscular dystrophy (DMD). Eteplirsen administered once weekly at 30mg/kg over 24 weeks resulted in a statistically significant (p ≤ 0.002) increase in novel dystrophin (22.5% dystrophin-positive fibers as...

More Releases

In the News

Bad Timing for a Promising Stock April 7, 2012

#1 in Washington State October 19, 2011	Waiting and Hoping April 2, 2012	AVI BioPharma Mulls Deal After Mixed Data With Muscular Dystrophy Drug April 6, 2012
Bothell bio-tech firm at forefront of trying to defuse real-life 'Contagion's Sep 13, 2011	Biotech firm prepares for real-life killer bugs September 12, 2001	Bothell company decoding mystery viruses and bacteria King5 Healthlink Chris Garabedian, CEO and Patrick Iversen, PhD, Senior Vice President of Research and Innovation September 8, 2011
Interview Chris Garabedian, CEO AVI BioPharma June 10, 2011	Biotech, People, Life Sciences Xconomy June 2, 2011	Going Viral The New Yorker Jan. 31, 2011

Annual Report

AVI 2011 Annual Report on Form 10-K AVI 2010 Annual Report on Form 10-K AVI 2009 Annual Report on Form 10-K AVI 2008 Annual Report on Form 10-K AVI 2007 Annual Report on Form 10-K

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.